Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Short-term Investments (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Short-term Investments for 4 consecutive years, with $244.0 million as the latest value for Q4 2025.

  • For Q4 2025, Short-term Investments fell 40.0% year-over-year to $244.0 million; the TTM value through Dec 2025 reached $244.0 million, down 40.0%, while the annual FY2025 figure was $244.0 million, 40.0% down from the prior year.
  • Short-term Investments was $244.0 million for Q4 2025 at Day One Biopharmaceuticals, down from $408.3 million in the prior quarter.
  • The five-year high for Short-term Investments was $439.7 million in Q1 2025, with the low at $47.6 million in Q1 2024.
  • Historically, Short-term Investments has averaged $253.9 million across 4 years, with a median of $253.6 million in 2022.
  • The largest annual shift saw Short-term Investments crashed 82.32% in 2024 before it skyrocketed 824.57% in 2025.
  • Over 4 years, Short-term Investments stood at $257.0 million in 2022, then tumbled by 47.25% to $135.6 million in 2023, then surged by 200.05% to $406.8 million in 2024, then tumbled by 40.0% to $244.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $244.0 million in Q4 2025, $408.3 million in Q3 2025, and $417.5 million in Q2 2025.